Skip to main content
SpringerLink
Log in

Cytokines and Related Metabolic Markers in Adult Neuropsychiatric Disorders: Possible Roles in Clinical Application

  • Chapter
Immunology and Psychiatry

Part of the book series: Current Topics in Neurotoxicity ((Current Topics Neurotoxicity,volume 8))

  • 1371 Accesses

Abstract

The importance of inflammatory response system activation indicated by abnormalities in cytokines and related metabolic markers in adult psychiatric disorders has been well studied and documented. The important aspects were reported not only in terms of pathophysiological mechanisms but also from the aspect of early diagnosis, prediction of the course of disease and prediction of response to treatment and subgrouping of clinical diagnostic groups. Future application of those markers in early diagnosis, prediction and prevention of suicide and personalized medicine for choice of treatment, either with psychotropic medications or adjuvant therapy, is necessary. The innovation effort to bring those results to application is challenging. New therapeutic developments should be carried out with great care. The past and present findings from the aspect of clinical applications and future perspectives are discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52(2):293–304.

    CAS  PubMed  Google Scholar 

  • Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113(2):296–320.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Andreazza AC, Gildengers A, Rajji TK, Zuzarte PM, Mulsant BH, Young LT. Oxidative stress in older patients with bipolar disorder. Am J Geriatr Psychiatry. 2015;23(3):314–9.

    Google Scholar 

  • Bender DA. Effects of a dietary excess of leucine and of the addition of leucine and 2-oxo-isocaproate on the metabolism of tryptophan and niacin in isolated rat liver cells. Br J Nutr. 1989;61(3):629–40.

    CAS  PubMed  Google Scholar 

  • Bender DA, McCreanor GM. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans. 1985;13(2):441–3.

    CAS  PubMed  Google Scholar 

  • Bentsen H, Osnes K, Refsum H, Solberg DK, Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013;3:e335.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.

    CAS  PubMed  Google Scholar 

  • Birmaher B, Rabin BS, Garcia MR, Jain U, Whiteside TL, Williamson DE, al-Shabbout M, Nelson BC, Dahl RE, Ryan ND. Cellular immunity in depressed, conduct disorder, and normal adolescents: role of adverse life events. J Am Acad Child Adolesc Psychiatry. 1994;33(5):671–78.

    Google Scholar 

  • Board F, Wadeson R, Persky H. Depressive affect and endocrine functions; blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. AMA Arch Neurol Psychiatry. 1957;78(6):612–20.

    CAS  PubMed  Google Scholar 

  • Bradley AJ, Dinan TG. A systematic review of hypothalamic–pituitary–adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol. 2010;24(4 Suppl):91–118.

    PubMed Central  PubMed  Google Scholar 

  • Busse M, Busse S, Myint AM, Gos T, Dobrowolny H, Müller UJ, Bogerts B, Bernstein HG, Steiner J. Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci. 2014 (submitted).

    Google Scholar 

  • Campuzano O, Castillo-Ruiz MM, Acarin L, Castellano B, Gonzalez B. Distinct pattern of microglial response, cyclooxygenase-2, and inducible nitric oxide synthase expression in the aged rat brain after excitotoxic damage. J Neurosci Res. 2008;86(14):3170–83.

    CAS  PubMed  Google Scholar 

  • Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70(2):175–82.

    CAS  PubMed  Google Scholar 

  • Carlin JM, Borden EC, Sondel PM, Byrne GI. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol. 1987;139(7):2414–8.

    CAS  PubMed  Google Scholar 

  • Carroll BJ, Martin FI, Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. Br Med J. 1968a;3(5613):285–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Carroll BJ, Martin FI, Davies B. Pituitary–adrenal function in depression. Lancet. 1968b;1(7556):1373–4.

    CAS  PubMed  Google Scholar 

  • Chandley MJ, Szebeni A, Szebeni K, Crawford JD, Stockmeier CA, Turecki G, Kostrzewa RM, Ordway GA. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol. 2014:17(10):1569–78.

    Google Scholar 

  • Chen S, Averett NT, Manelli A, Ladu MJ, May W, Ard MD. Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia. J Alzheimers Dis. 2005;7(1):25–35.

    CAS  PubMed  Google Scholar 

  • Chen CY, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry. 2010;32(6):647. e647–649.

    PubMed  Google Scholar 

  • Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol. 2001;120(1–2):190–8.

    CAS  PubMed  Google Scholar 

  • Claes S, Myint AM, Domschke K, Del-Favero J, Entrich K, Engelborghs S, De Deyn P, Mueller N, Baune B, Rothermundt M. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 2011;188(3):355–60.

    CAS  PubMed  Google Scholar 

  • Condray R, Dougherty Jr GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol. 2011;14(6):756–67.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Connor MJ, Pheasant AE, Blair JA. The identification of p-acetamidobenzoate as a folate degradation product in rat urine. Biochem J. 1979;178(3):795–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Depboylu C, Weihe E, Eiden LE. COX1 and COX2 expression in non-neuronal cellular compartments of the rhesus macaque brain during lentiviral infection. Neurobiol Dis. 2011;42(1):108–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952–5.

    CAS  PubMed  Google Scholar 

  • Dinnerstein AJ, Halm J. Modification of placebo effects by means of drugs: effects of aspirin and placebos on self-rated moods. J Abnorm Psychol. 1970;75(3):308–14.

    CAS  PubMed  Google Scholar 

  • Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, Drexhage HA. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10(1):59–76.

    CAS  PubMed  Google Scholar 

  • Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313(1–2):96–8.

    CAS  PubMed  Google Scholar 

  • Erhardt S, Schwieler L, Engberg G. Kynurenic acid and schizophrenia. Adv Exp Med Biol. 2003;527:155–65.

    CAS  PubMed  Google Scholar 

  • Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743–52.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fekadu A, Mesfin M, Medhin G, Alem A, Teferra S, Gebre-Eyesus T, Seboxa T, Assefa A, Hussein J, Lemma MT, et al. Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial. Trials. 2013;14:406.

    PubMed Central  PubMed  Google Scholar 

  • Fernstrom JD. Effects on the diet on brain neurotransmitters. Metabolism. 1977;26(2):207–23.

    CAS  PubMed  Google Scholar 

  • Fischman LG. Dreams, hallucinogenic drug states, and schizophrenia: a psychological and biological comparison. Schizophr Bull. 1983;9(1):73–94.

    CAS  PubMed  Google Scholar 

  • Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med. 2001;39(8):691–4.

    CAS  PubMed  Google Scholar 

  • Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol. 2012;32(2):179–85.

    CAS  PubMed  Google Scholar 

  • Gabbay V, Liebes L, Katz Y, Liu S, Mendoza S, Babb JS, Klein RG, Gonen O. The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):37–44.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gal EM, Sherman AD. l-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5(3):223–39.

    CAS  PubMed  Google Scholar 

  • Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol. 2009;24(4):277–86.

    CAS  PubMed  Google Scholar 

  • Garcia-Miss Mdel R, Perez-Mutul J, Lopez-Canul B, Solis-Rodriguez F, Puga-Machado L, Oxte-Cabrera A, Gurubel-Maldonado J, Arankowsky-Sandoval G. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 2010;44(7):441–6.

    PubMed  Google Scholar 

  • Gos T, Myint AM, Schiltz K, Meyer-Lotz G, Dobrowolny H, Busse S, Muller UJ, Mawrin C, Bernstein HG, Bogerts B, et al. Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav Immun. 2014;41:59–64.

    Google Scholar 

  • Grant RS, Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem. 1998;70(4):1759–63.

    CAS  PubMed  Google Scholar 

  • Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep. 2000;5(2–3):101–4.

    CAS  PubMed  Google Scholar 

  • Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905.

    PubMed Central  PubMed  Google Scholar 

  • Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, Brew BJ. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep. 2000;5(2–3):108–11.

    CAS  PubMed  Google Scholar 

  • Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78(4):842–53.

    CAS  PubMed  Google Scholar 

  • Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005a;49(1):15–23.

    PubMed  Google Scholar 

  • Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation. 2005b;2:16.

    PubMed Central  PubMed  Google Scholar 

  • Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1–39.

    CAS  PubMed  Google Scholar 

  • Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–79.

    CAS  PubMed  Google Scholar 

  • Halaris A, Myint AM, Savant V, Meresh E, Lim C, Hoppensteadt D, Fareed J, Sinacore J. Does Escitalopram reduce neurotoxic effects in major depression? Psychiatry Research. 2015. Accepted.

    Google Scholar 

  • Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from l-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain. 1993;116(Pt 6):1425–50.

    PubMed  Google Scholar 

  • Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1996;320(Pt 2):595–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463–73.

    CAS  PubMed  Google Scholar 

  • Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol. 2001;16(3):203–18.

    CAS  PubMed  Google Scholar 

  • Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000;54(5):565–72.

    CAS  PubMed  Google Scholar 

  • Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, Samuelsson M, Traskman-Bendz L, Brundin L. Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology. 2013;38(6):853–62.

    CAS  PubMed  Google Scholar 

  • Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8.

    CAS  PubMed  Google Scholar 

  • Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, Gardner R, Lundkvist GB, Urbanska EM, Karlsson H. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J Psychiatr Res. 2013;47(11):1815–23.

    PubMed  Google Scholar 

  • Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1–2):123–31.

    PubMed  Google Scholar 

  • Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women’s health study cognitive cohort. BMJ. 2007;334(7601):987.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kargar M, Yousefi A, Mojtahedzadeh M, Akhondzadeh S, Artounian V, Abdollahi A, Ahmadvand A, Ghaeli P. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly. 2014;144:w13880.

    PubMed  Google Scholar 

  • Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, Wehring HJ. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res. 2011;133(1–3):257–8.

    PubMed  Google Scholar 

  • Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014;215(3):540–6.

    CAS  PubMed  Google Scholar 

  • Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23(2):423–32.

    CAS  PubMed  Google Scholar 

  • Kim YK, Lee MS, Suh KY. Decreased interleukin-2 production in Korean schizophrenic patients. Biol Psychiatry. 1998;43(9):701–4.

    CAS  PubMed  Google Scholar 

  • Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res. 2000;44(3):165–75.

    CAS  PubMed  Google Scholar 

  • Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, Steinbusch HW. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004a;129(3):267–72.

    CAS  PubMed  Google Scholar 

  • Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, Leonard BE. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004b;28(7):1129–34.

    CAS  PubMed  Google Scholar 

  • Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 2009;59(2):123–9.

    CAS  PubMed  Google Scholar 

  • Knox WE. Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system. Br J Exp Pathol. 1951;32(5):462–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21(2):199–206.

    CAS  PubMed  Google Scholar 

  • Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):520–7.

    CAS  PubMed  Google Scholar 

  • Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969;1(7586):132–6.

    CAS  PubMed  Google Scholar 

  • Lardy HA. The role of tryptophan metabolites in regulating gluconeogenesis. Am J Clin Nutr. 1971;24(7):764–5.

    CAS  PubMed  Google Scholar 

  • Leklem JE. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr. 1971;24(6):659–72.

    CAS  PubMed  Google Scholar 

  • Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138–49.

    CAS  PubMed  Google Scholar 

  • Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6(4):312–24.

    CAS  PubMed  Google Scholar 

  • Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150(9):1408–10.

    CAS  PubMed  Google Scholar 

  • Lieberman HR, Wurtman RJ, Emde GG, Coviella IL. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol. 1987;7(5):315–20.

    CAS  PubMed  Google Scholar 

  • Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998;32(1):9–15.

    CAS  PubMed  Google Scholar 

  • Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92.

    CAS  PubMed  Google Scholar 

  • Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry. 1983;40(4):405–6.

    CAS  PubMed  Google Scholar 

  • Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014;153(1–3):169–76.

    PubMed  Google Scholar 

  • Loo H, Saiz-Ruiz J, Costa e Silva J, Ansseau M, Herrington R, Vaz-Serra A, Dilling H, de Risio S. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord. 1999;56(2–3):109–18.

    Google Scholar 

  • Maes M. Cytokines in major depression. Biol Psychiatry. 1994;36(7):498–9.

    CAS  PubMed  Google Scholar 

  • Maes M, Lambrechts J, Suy E, Vandervorst C, Bosmans E. Absolute number and percentage of circulating natural killer, non-MHC-restricted T cytotoxic, and phagocytic cells in unipolar depression. Neuropsychobiology. 1994;29(4):157–63.

    CAS  PubMed  Google Scholar 

  • Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141–52.

    CAS  PubMed  Google Scholar 

  • Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20(4):370–9.

    CAS  PubMed  Google Scholar 

  • Mann JJ, Oquendo MA, Watson KT, Boldrini M, Malone KM, Ellis SP, Sullivan G, Cooper TB, Xie S, Currier D. Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. Depress Anxiety. 2014;31(10):814–21.

    CAS  PubMed  Google Scholar 

  • Marty S, Wehrle R, Sotelo C. Neuronal activity and brain-derived neurotrophic factor regulate the density of inhibitory synapses in organotypic slice cultures of postnatal hippocampus. J Neurosci. 2000;20(21):8087–95.

    CAS  PubMed  Google Scholar 

  • Mathers C, Loncar D. Updated projections of global mortality and burden of disease, 2002–2030: data sources, methods and results. Geneva: WHO; 2005.

    Google Scholar 

  • McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704.

    Google Scholar 

  • Mehta D, Raison CL, Woolwine BJ, Haroon E, Binder EB, Miller AH, Felger JC. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun. 2013;31:205–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20(10):469–73.

    CAS  PubMed  Google Scholar 

  • Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323–38.

    PubMed Central  PubMed  Google Scholar 

  • Meyer U, Feldon J, Schedlowski M, Yee BK. Immunological stress at the maternal–foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun. 2006;20(4):378–88.

    CAS  PubMed  Google Scholar 

  • Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15(3):618–29.

    CAS  PubMed  Google Scholar 

  • Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073–1074:25–37.

    PubMed  Google Scholar 

  • Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):304–7.

    CAS  PubMed  Google Scholar 

  • Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2):222–6.

    CAS  PubMed  Google Scholar 

  • Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25.

    CAS  PubMed  Google Scholar 

  • Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81(4):247–65.

    CAS  PubMed  Google Scholar 

  • Moffett JR, Blinder KL, Venkateshan CN, Namboodiri MA. Differential effects of kynurenine and tryptophan treatment on quinolinate immunoreactivity in rat lymphoid and non-lymphoid organs. Cell Tissue Res. 1998;293(3):525–34.

    CAS  PubMed  Google Scholar 

  • Müller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub. 2013;25(3):292–8.

    PubMed  Google Scholar 

  • Muller N, Dobmeier P, Empl M, Riedel M, Schwarz M, Ackenheil M. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur Psychiatry. 1997;12(6):294–9.

    CAS  PubMed  Google Scholar 

  • Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.

    CAS  PubMed  Google Scholar 

  • Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119–33.

    PubMed  Google Scholar 

  • Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252–7.

    CAS  PubMed  Google Scholar 

  • Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood. 1994;83(5):1408–11.

    CAS  PubMed  Google Scholar 

  • Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279(8):1375–85.

    CAS  PubMed  Google Scholar 

  • Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord. 2005;88(2):167–73.

    CAS  PubMed  Google Scholar 

  • Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007a;98(1–2):143–51.

    CAS  PubMed  Google Scholar 

  • Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007b;102(1–3):65–72.

    CAS  PubMed  Google Scholar 

  • Myint AM, Schwarz M, Verkerk R, Scharpe S, Steinbusch HWM, Leonard BE, Kim YK. Imbalance of kynurenine metabolites in drug naive schizophrenia. Brain Behav Immun. 2011a;25(8):6.

    Google Scholar 

  • Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun. 2011b;25(8):1576–81.

    CAS  PubMed  Google Scholar 

  • Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schule C, Zill P, Muller N, Rupprecht R, Schwarz MJ. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav Immun. 2013;31:128–33.

    CAS  PubMed  Google Scholar 

  • Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87–94.

    CAS  PubMed  Google Scholar 

  • Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39(6):1230–41.

    PubMed Central  PubMed  Google Scholar 

  • Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry. 1988;23(4):326–34.

    CAS  PubMed  Google Scholar 

  • Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70(1):299–307.

    CAS  PubMed  Google Scholar 

  • Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254(5037):1515–8.

    CAS  PubMed  Google Scholar 

  • Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci. 2008;45:19–25.

    PubMed  Google Scholar 

  • Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982;247(1):184–7.

    CAS  PubMed  Google Scholar 

  • Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 1999;51(3):533–91.

    CAS  PubMed  Google Scholar 

  • Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15(4):393–403.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–92.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Reininghaus EZ, McIntyre RS, Reininghaus B, Geisler S, Bengesser SA, Lackner N, Hecht K, Birner A, Kattnig F, Unterweger R, et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014;16(4):432–40.

    CAS  PubMed  Google Scholar 

  • Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H. Inflammatory markers in major depression and melancholia. J Affect Disord. 2001;63(1–3):93–102.

    CAS  PubMed  Google Scholar 

  • Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Harris MS, Hill SK, Reilly JL, Sweeney JA. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr Res. 2013;146(1–3):138–43.

    PubMed Central  PubMed  Google Scholar 

  • Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, et al. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull. 2014;40(6):1374–84.

    PubMed  Google Scholar 

  • Sachar EJ, Hellman L, Fukushima DK, Gallagher TF. Cortisol production in depressive illness. A clinical and biochemical clarification. Arch Gen Psychiatry. 1970;23(4):289–98.

    CAS  PubMed  Google Scholar 

  • Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.

    PubMed Central  PubMed  Google Scholar 

  • Salter M, Pogson CI. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985;229(2):499–504.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sartorius N. Concepts of depression: sporadic revolutions of continuous evolution. Hum Psychopharmacol. 2001;16(S1):S3–6.

    PubMed  Google Scholar 

  • Schafer M, Messer T, Wegner U, Schmid-Wendtner MH, Volkenandt M. Psychiatric side effects during adjuvant therapy with interferon-alphain patients with malignant melanoma. Clinical evaluation as well as diagnostic and therapeutic possibilities. Hautarzt. 1999;50(9):654–8.

    CAS  PubMed  Google Scholar 

  • Schwarcz R, Whetsell Jr WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219(4582):316–8.

    CAS  PubMed  Google Scholar 

  • Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50(7):521–30.

    CAS  PubMed  Google Scholar 

  • Schwarz MJ, Myint AM, Holdenrieder S, Seemüller F, Tischinger M, Riedel M, Müller N. The association between peripheral and CSF kynurenine metabolites in patients with affective disorders and schizophrenia. Brain Behav Imm. Under review.

    Google Scholar 

  • Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic–pituitary–adrenal axis function: implications for the pathophysiology of depression. Life Sci. 1998;62(22):1985–98.

    CAS  PubMed  Google Scholar 

  • Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. Br J Psychiatry. 2003;182:221–7.

    PubMed  Google Scholar 

  • Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol. 1996;78(1):83–5.

    CAS  PubMed  Google Scholar 

  • Singh B, Bera NK, Nayak CR, Chaudhuri TK. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine. 2009;47(1):1–5.

    CAS  PubMed  Google Scholar 

  • Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci. 1995;762:474–6.

    CAS  PubMed  Google Scholar 

  • Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res. 1996;64(3):161–7.

    CAS  PubMed  Google Scholar 

  • Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry. 2009;65(6):481–8.

    CAS  PubMed  Google Scholar 

  • Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neurotransmitters: possible interactions in depression? Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:268–76.

    CAS  PubMed  Google Scholar 

  • Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almas B, Lovas K, Agartz I, et al. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry. 2011;72(11):1515–21.

    CAS  PubMed  Google Scholar 

  • Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, Do KQ. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophr Res. 2014;1–11. In press [Epub ahead of print].

    Google Scholar 

  • Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014;42:93–115.

    CAS  PubMed  Google Scholar 

  • Szebeni A, Szebeni K, DiPeri T, Chandley MJ, Crawford JD, Stockmeier CA, Ordway GA. Shortened telomere length in white matter oligodendrocytes in major depression: potential role of oxidative stress. Int J Neuropsychopharmacol. 2014;17(10):1579–1589.

    Google Scholar 

  • Takahashi T, Wood SJ, Soulsby B, McGorry PD, Tanino R, Suzuki M, Velakoulis D, Pantelis C. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res. 2009;108(1–3):49–56.

    PubMed  Google Scholar 

  • Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(1 Suppl 1):39–47.

    CAS  PubMed  Google Scholar 

  • Watanabe Y, Fujiwara M, Yoshida R, Hayaishi O. Stereospecificity of hepatic l-tryptophan 2,3-dioxygenase. Biochem J. 1980;189(3):393–405.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab. 2002;3(2):159–73.

    CAS  PubMed  Google Scholar 

  • Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538–44.

    CAS  PubMed  Google Scholar 

  • Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry. 2006;60(1):77–9.

    CAS  PubMed  Google Scholar 

  • Widner B, Fuchs D, Leblhuber F, Sperner-Unterweger B. Does disturbed homocysteine and folate metabolism in depression result from enhanced oxidative stress? J Neurol Neurosurg Psychiatry. 2001;70(3):419.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wilde MI, Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 1995;49(3):411–39.

    CAS  PubMed  Google Scholar 

  • Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15(4):357–76.

    CAS  PubMed  Google Scholar 

  • Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.

    CAS  PubMed  Google Scholar 

  • Yao JK, Dougherty Jr GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010;15(9):938–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yasui H, Takai K, Yoshida R, Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci U S A. 1986;83(17):6622–6.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The work of Myint AM was funded be European Collaborative Project, Moodinflame (Grant No. 22963) and Marie-Curie IAPP Project, Psych-aid (Grant No. 286334).

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, PsychoNeuroImmunology Research Group, Ludwig-Maximilians-University Munich, Munich, Germany

    Aye-Mu Myint

  2. Otto von Guericke University, Magdeburg, Germany

    Aye-Mu Myint

  3. School for Mental Health and Neuroscience, Faculty of Medicine, Maastricht University, Universiteitssingel 40, 6229, Maastricht, The Netherlands

    Aye-Mu Myint

  4. Institut fuer Laboratoriumsmedizin, Klinikum der Universitaet Muenchen, Muenchen, Germany

    Markus J. Schwarz

Authors
  1. Aye-Mu Myint
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus J. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus J. Schwarz .

Editor information

Editors and Affiliations

  1. University Clinic, Campus Innenstadt Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany

    Norbert Müller

  2. University Clinic, Campus Innenstadt PsychoNeuroImmunology Research Group, Ludwig-Maximilians-University Munich, Munich, Germany

    Aye-Mu Myint

  3. Institute fuer Laboratoriumsmedizin, Klinikum der Universitaet Muenchen, Muenchen, Germany

    Markus J. Schwarz

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Myint, AM., Schwarz, M.J. (2015). Cytokines and Related Metabolic Markers in Adult Neuropsychiatric Disorders: Possible Roles in Clinical Application. In: Müller, N., Myint, AM., Schwarz, M. (eds) Immunology and Psychiatry. Current Topics in Neurotoxicity, vol 8. Springer, Cham. https://doi.org/10.1007/978-3-319-13602-8_10

Download citation

Publish with us

Policies and ethics

Search

Navigation